Aurobindo Pharma Gets USFDA Nod for Rare Disease Treatment

Hyderabad-based Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (USFDA) for its generic version of glycerol phenylbutyrate oral liquid, strengthening its presence in the US generics market.

The approved drug, available in a 1.1 g/mL oral liquid form, is a generic equivalent of Ravicti, which is used to treat patients with Urea Cycle Disorders (UCDs). These are rare inherited conditions where the body cannot effectively remove ammonia, leading to serious health risks if untreated. The medication helps reduce ammonia levels and is typically prescribed when dietary management alone is not enough.

With this approval, Aurobindo Pharma aims to offer a more affordable treatment option for patients in the United States who require long-term therapy. The company said the product will be manufactured at its Unit-III facility and will be launched soon, indicating it is ready to enter the market without delay.

According to industry estimates from IQVIA, the US market for glycerol phenylbutyrate oral liquid was valued at around $50 million for the 12 months ending February 2026. While relatively niche, the segment offers steady demand due to the chronic nature of the condition and limited treatment options available.

Also Read: Centre Calls for Uniform Hospital Rates to Curb Rising Costs

This latest approval also adds to Aurobindo Pharma’s growing portfolio of ANDA approvals. The company now has a total of 579 approvals, including 556 final approvals and 23 tentative ones. This reflects its consistent focus on regulated markets like the US, where compliance and quality standards are critical.

Industry observers note that Aurobindo’s strategy of targeting specialty drugs and rare disease treatment segments could support its long-term growth. By focusing on areas with fewer competitors and high unmet medical needs, the company is positioning itself beyond traditional generics and into more value-driven segments of the pharmaceutical market.